1. Negrin RS. Sources of hematopoietic stem cells (online) (cited 2015 january 28). Available from: URL: http://wwwuptodatecom/contents/sources- ofhematopoietic- stem-cells-source. 2015.
2. Batmaz, L . (2015). Allojenik Kök Hücre nakli vericilerinde mobilizasyon
başarısına etkili olan faktörlerin araştırılması. (Uzmanlık Tezi) .YÖK Ulusal
Tez Merkezi veri tabanından elde edildi. (399128).
3. Sargin, D. (y.y.). Kök Hücre Plastisitesi Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature. 2006;441(7097):1068-74.
4. S T. Rocheteau P, Le Roux I. Asymmetric cell divisions and asymmetric cell fates. Annu Rev Cell Dev Biol 2009. 2009;25:671.
5. Vescovi A, Gritti A, Cossu G, Galli R. Neural stem cells: plasticity and their transdifferentiation potential. Cells, tissues, organs. 2002;171(1):64-76.
6. Şahin, F., Saydam, G., & Omay, S. B. (2005). Kök Hücre Plastisitesi ve Klinik Pratikte Kök Hücre Tedavisi. TürkHematolojı̇ OnkolojiDergı̇sı̇, 15(1), 48–56. 7. Kök Hücreler. (2007, Ocak). http://yunus.hacettepe.edu.tr/~mergen/derleme/
d_stem.pdf
8. Pansky A, Roitzheim B, Tobiasch E. Differentiation potential of adult human mesenchymal stem cells. Clinical laboratory. 2007;53(1-2):81-4.
9. Ross J, Li L. Recent advances in understanding extrinsic control of hematopoietic stem cell fate. Current opinion in hematology. 2006;13(4):237 42.
10. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science.1999;284(5411):143-7.
11. Motabi IH, DiPersio JF. Advances in stem cell mobilization. Blood reviews. 2012;26(6):267-78
12. Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. The Journal of experimental medicine. 2011;208(3):421-8.
13. Lymperi S, Ferraro F, Scadden DT. The HSC niche concept has turned 31. Has our knowledge matured? Annals of the New York Academy of Sciences.2010;1192:12-8.
14. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118(2):149-61.
15. Thoren LA, Liuba K, Bryder D, Nygren JM, Jensen CT, Qian H, et al. Kit regulates maintenance of quiescent hematopoietic stem cells. Journal of immunology. 2008;180(4):2045-53.
16. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell stem cell. 2007;1(6):685-97. 17. 17.{Formatting Citation} Uçkan Çetinkaya, D., & Kilic, E. (2014).
HEMATOPOETİK KÖK HÜCRE VE MİKROÇEVRE İLİŞKİSİ.
18. Negrin RS. Sources of hematopoietic stem cells (online) (cited 2015 january 28). Available from: URL: http://wwwuptodatecom/contents/sources-of hematopoietic-stem-cells-source. 2015.
19. Fruehauf S, Schmitt K, Veldwijk MR, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999; 105:786.
20. Kröger N, Renges H, Krüger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111:761.
21. ertem, m. (2006, 04 29). türk hematoloji derneği. http://www.thd.org.tr: www.thd.org.tr/thdData/.../29_04_2006_mehmet_ertem_11-30_12-00.pdf adresinden alındı
22. Motabi IH, DiPersio JF. Advances in stem cell mobilization. Blood reviews. 2012;26(6):267-78.
23. Arend WP. A.J., Clemmons DR, Drazen JM, Griggs RC, Larusso N. Hematopoetic Stem Cell Transplantation, Ausiello D: New York: Lee Goldman, Buston.. Cecil Medicine, PS Vose JM, Editor. 2008:p. 1328-32. 24. Robert S Negrin M. Preparative regimens for hematopoietic cell
transplantation. cited: Jan 07, 2016
25. Beksaç M. HLA Doku Gruplarının Değelendilmesindeki Ana Özellikler, Akrabadışı Verici Taraması ve Uygun Verici Seçiminde Uyulması Gereken Hususlar. Hematolog. 2011;1(1):22-32.
26. http://factwebsite.org/Inner.aspx?id=163 (Accessed on February 17, 2015) 27. Joseph H Antin, MD Christine N Duncan, MD. Feb 22, 2017. Evaluation of
the hematopoietic cell transplantation donor. uptodate. [Çevrimiçi] Feb 22, 2017.
28. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious
complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.
29. US Food and Drug Administration. Testing HCT/P donors: Specific
requirements.
http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/TissueSafety/uc m151757.htm (Accessed on December 02, 2014).
30. US Food and Drug Administration. Donor Screening Recommendations to
Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products: Guidance for Industry, March 2016.
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCompliance
RegulatoryInformation/Guidances/Tissue/UCM488582.pdf (Accessed on
March 07, 2016).
31. Niederwieser D, Gentilini C, Hegenbart U, Lange T, Moosmann P, Ponisch W, et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors? Bone marrow transplantation. 2004;34(8):657-65.
32. Horowitz MM, Confer DL. Evaluation of hematopoietic stem cell donors. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2005:469-75.
33. Chen SH, Wang TF, Yang KL. Hematopoietic stem cell donation. International journal of hematology. 2013;97(4):446-55.
34. Vasiliu IM, Petri MA, Baer AN. Therapy with granulocyte colony stimulating factor in systemic lupus erythematosus may be associated with severe flares. The Journal of rheumatology. 2006;33(9):1878-80.
35. Parkkali T, Volin L, Siren MK, Ruutu T. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone marrow transplantation. 1996;17(3):433-4.
36. Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. The Journal of rheumatology. 1997;24(11):2153-7.
37. 37. Horowitz MM, DL. Evaluation of hematopoietic stem cell donors. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2005:469-75.
38. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. The New England journal of medicine. 2001;344(3):175-81.
39. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100(5):1525-31.
40. Robert S Negrin M. Sources of hematopoietic stem cells. cited june 2015. http://wwwuptodatecom/contents/sources-of-hematopoietic-stem-cells?
source=preview&language=en-US&anchor=H16&selectedTitle= 3~150# H16. 41. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow
allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001;98(10):2900-8.
42. Takeyama K, Ohto H. PBSC mobilization. Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis. 2004;31(3):233-43.
43. Richman CM, Weiner RS, Yankee RS. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031–9.
44. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulated factor. Blood 1995;85:1655–8.
45. Schmitz N, Dreger P, Suttorp M. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony- stimulating factor). Blood 1995;85:1666–72.
46. Weaver CH, Buckner CD, Longin K, Appelbaum FR, Rowley S, Lilleby K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colonystimulating factor. Blood. 1993;82(7):1981-4.
47. Anderlini F, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997;37:507–12.
48. Höglund M, Smedmyr B, Bengtsson M, et al. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy donors – comparative study. Eur J Haematol 1997;59:177–83.
49. Watts MJ, Addison I, Long SG, et al. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997;98:474–9.
50. Kröger N, Renges H, Kru¨ger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000;111:761–5.
51. Kröger N, Zeller W, Hasan HT, et al. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering doses (2 · 5 lg/kg) compared to a single dose (1 · 10 lg/kg). Bone Marrow Transplant 1999;23:125–9.
52. Renfroe H, Arnold M, Vaughn L, Harvey RD, Hamilton E, Lonial S, Khoury HJ, Kaufman JL, Lechowicz MJ, Flowers CR, Waller EK.A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. Transfusion. 2011 (Epub ahead of print)
53. Arslan Ö. Moog R, Periferik Kan Kök Hücrelerinin Mobilizasyonu ve Geniş Hacimli Lökoferez ile Toplanması Hematolog. 2011;1-1:33-42.
54. Malachowski ME, Comenzo RL, Hillyer CD, Tiegerman KO, Berkman EM. Largevolume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 1992;32:732–5.
55. Smolowicz AG, Villman K, Tidefelt U. Large-volume apheresis for the harvest of peripheral blood progenitor cells for autologous transplantation. Transfusion 1997;37:188–92.
56. Humpe A, Riggert J, Munzel U, et al. A prospective, randomized, sequential, crossover trial of large-volume versus normal-volume leukapheresis procedures: effect on progenitor cells and engraftment. Transfusion 1999;39:1120–7.
57. Menichella G, Lai M, Serafini R, et al. Large volume leukapheresis for collecting hemopoietic progenitors: role of CD34+ precount in predicting successful collection. Int J Art Organs 1999;22:334–41.
58. Torrabadella M, Olive T, Ortega JJ, Massuet L. Enhanced HPC recruitment in children using LVL and a new automated apheresis system. Transfusion 2000;40:404–10.
59. Bojko P, Scharifi M, Sto¨ ssel K, Seeber S. Comparison of processing four and five times the patients’ blood volume during peripheral blood stem cell collection and analysis of CD34-38- and CD34CD49d+ subsets during apheresis. J Cancer Res Oncol 2002;128:19–28.
60. Accorsi P, Dell’Isola M, Bonfini T, et al. Large volume leukapheresis with AMICUS cell separator in peripheral blood stem cell autologous transplant. Transfus Apheresis Sci 2001;24:79–83.
61. Hillyer CD, Tiegerman KO, Berkman WM. Increase in circulating colony- forming units granulocyte-macrophage during large-volume leukapheresis: Evaluation of a new cell separator. Transfusion 1991;31:327–32.
62. Alegre A, Diaz MA, Madero L, et al. Large-volume leukapheresis for peripheral blood stem cell collection in children: a simplified single-apheresis approach. Bone Marrow Transpl 1996;17:923–7.
63. Gorlin JB, Vamvakas EC, Cooke E, Galacki D, Geha R, Humphreys D, et al. Largevolume leukapheresis in pediatric patients: processing more blood
diminishes the apparent magnitude of intra-apheresis recruitment. Transfusion 1996;36:879–85.
64. Dreger P, Marquardt P, Haferlach T, et al. Effective mobilisation of peripheral blood progenitor cells with Dexa-BEAM and G-CSF: timing of harvesting and composition of leukapheresis product. Br J Cancer 1993;68:950–7.
65. Cassens U, Barth IM, Baumann C, et al. Factors affecting the efficacy of peripheral blood progenitor cell collection by large-volume leukapheresis with standardized processing volumes. Transfusion 2004;44:1593–602.
66. Abrahamsen JF, Stamnesfet S, Liseth K, Hervig T, Bruserud O. Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normalvolume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells. Transfusion 2005;45:248–53.
67. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999;353:555.
68. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201(8):1307–18. 69. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley
SD, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867– 74.
70. Burroughs L, Mielcarek M, Little MT, Bridger G, Macfarland R, Fricker S, et al. Durable engraftment of AMD3100- mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005;106:4002–8.
71. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG- CSF, Neulasta). Curr Pharm Des 2004;10:1235–44.
72. Morrison SJ, Wright DE, Weissman IL. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(5):1908-13.
73. 73 . Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ. Mobilization by either cyclophosphamide or granulocyte colony-
stimulating factor transforms the bone marrow into a highly proteolytic environment.Experimental hematology. 2002;30(5):440-9.
74. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. The Journal of clinical investigation. 2003;111(2):187-96.
75. Hashimoto S, Itoh M, Nishimura M, Asai T. Effect of filgrastim administration for steady-state mobilization of peripheral blood stem cells. Therapeutic apheresis: official journal of the International Society for Apheresis and the Japanese Society for Apheresis. 2002;6(6):431-6.
76. Kroger N, Renges H, Kruger W, Gutensohn K, Loliger C, Carrero I, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. British journal of haematology. 2000;111(3):761-5.
77. Engelhardt M, Bertz H, Afting M, Waller CF, Finke J. High-versus standard dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999;17(7):2160-72.
78. Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony- stimulating factor (G-CSF): impact of age, sex, donor weight and type of G- CSF used. British journal of haematology. 2006;134(5):517-25.
79. Winkler IG, Pettit AR, Raggatt LJ, Jacobsen RN, Forristal CE, Barbier V, et al. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia. 2012;26(7):1594-601.
80. Chow A, Lucas D, Hidalgo A, Mendez-Ferrer S, Hashimoto D, Scheiermann C, et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. The Journal of experimental medicine. 2011;208(2):261-71.
81. Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G- CSF receptor in monocytic cells is sufficient to mediate hematopoietic
progenitor mobilization by G-CSF in mice. The Journal of experimental medicine. 2011;208(2):251-60.
82. Engelhardt M, Bertz H, Afting M, et al. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol 1999;17:2160– 72.
83. Nuamah NM, Goker H, Kilic YA, et al. Spontaneous splenic rupture in a healthy allogeneic donor of peripheralblood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica 2006;91 ECR08.
84. de la Rubia J, de Arriba F, Arbona C, et al. Followup of healthy donors receiving granulocyte colonystimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008;93:735–40.
85. Tigue CC, McKoy JM, Evens AM, et al. Granulocytecolony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007;40:185–92. 86. Halter J, Kodera Y, Ispizua AU, et al. Severe events in donors after allogeneic
hematopoietic stem cell donation. Haematologica 2009;94:94–101.
87. Amrein K, Valentin A, Lanzer G, Drexler C. Adverse events and safety issues in blood donation-A comprehensive review. Blood Reviews 26 (2012) 33–42 88. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408
unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009;9(113):3604–11. 89. Halter J, Kodera Y, Ispizua AU, et al. Severe events in donors after allogeneic
hematopoietic stem cell donation. Haematologica 2009;94:94–101.
90. Hölig K, Kramer M, Kroschinsky F, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009 Oct 29;114(18):3757-63.
91. Kroschinsky F, Hölig K, Poppe-Thiede K, et al. Singledose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in
healthy family and unrelated donors. Haematologica. 2005 Dec;90(12):1665- 71.
92. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008 Aug 15;112(4):990-8.
93. Dönmez A. Donör Komplikasyonları, 7. Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi,Antalya, 2012 mart 08-10; 54-55
94. Bilgen, H. (2011). DONÖR AFEREZ KOMPLİKASYONLARI. XXXVII.
Ulusal Hematoloji Kongresi (s. 111-115). Ankara: Türk Hematoloji Derneği.
95. Jeffrey McCullough. Transfusion Medicine. Second Edition. Elsevier Churchill Livingstone, 2005Aferez Teknolojisi Esasları. 1. Ulusal Hemaferez Kongresi, 9-10 Ekim 2003.
96. McLeod BC, Price TH, Weinstein R. Apheresis: Principles and Practice, 2nd Edition Bethesda, MD:AABB Press, 2003.
97. Hoffman R, Benz JE, Shattil JS, Furie B, Cohen JH, Silberstein EL, McGlave P. Hematology Basic Principles and Practice. Fourth Edition, Elsevier Churchill Livingstone, 2005.
98. Ulusal Kan Merkezleri ve Transfüzyon Tıbbi Kursu (II), Kurs Kitabı, 15-20 Mart 1998.
99. Popovsky MA. Multicomponenet apheresis blood collection in the United States: current status and future directions.Transfus Apher Sci 2005;32:299- 304.
100. Gilcher RO. Apheresis: principles and technology of hemapheresis.In: Simon TL, Snyder EL, Stowell CP, Strauss RG,editors. Rossi’s principles of transfusion medicine. 3rd ed.Philadelphia (PA): Lippincott,Williams &Wilkins; 2002. p.648-58.
101. Wiltbank TB, Giordano GF. The safety profile of automated collections: an analysis of more than 1 million collections.Transfusion 2007;47:1002-5.
102. Winters JL. Complications of donor apheresis. J Clin Apher 2006;21:132-41. 103. Yuan S, Gornbein J, Smeltzer B, Ziman AF, Lu Q, Goldfinger D. Risk factors
for acute, moderate to severe donorreactions associated with multicomponent apheresis collections.Transfusion 2008;48:1213-19.
104. Newman BH, Pichette S, Pichette D, Dzaka E. Adverse effects in blood donors after whole-blood donation: A study of 1000 blood donors interviewed 3 weeks after whole-blood donation. Transfusion 2003;43:598-603
105. Ramakrishna L. Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfusion and Apheresis Science. 2005;32:63–72. 106. Confer DL. Miller J. P. Optimal Donor Selection: Beyond HLA. Biol Blood
Marrow Tr. 2007;13:83-6.
107. Weaver CH, Schwartzberg LS, Birch R, Greco FA, Hainsworth J, Drapkin R, et al. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 1997;3(2):83-90. 108. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, et al. Patient
characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 1994;83(12):3787-94.
109. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98(7):2043-51.
110. Carreras E, Jimenez M, Gomez-Garcia V, de la Camara R, Martin C, Martinez F, et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone marrow transplantation. 2006;37(1):33-40.
111. Bishop MR. TarantaloSR, Bieman PJ et al. Predictive factors for the identification of allogenic blood stem cell donors as poor mobilizers prior to stem cell colLection. . Blood pressure. 1997;90 (no:10,suppl, abst 2632, pp 592.).
112. Brown RA, Adkins D, Goodnough LT, Haug JS, Todd G, Wehde M, et al. Factors that influence the collection and engraftment of allogeneic peripheral blood stem cells in patients with hematologic malignancies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1997;15(9):3067-74.
113. Miflin G, Charley C, Stainer C, Anderson S, Hunter A, Russell N. Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. British journal of haematology. 1996;95(2):345- 8.
114. Bertani G, Santoleri L, Martino M, Fedele R, Moscato T, Marenco P, et al. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study. Transfusion. 2014;54(8):2028-33.
115. Motllo C, Sancho JM, Grifols JR, Junca J, Morgades M, Ester A, et al. Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. Cytotherapy. 2014;16(3):406-11.
116. Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone marrow transplantation. 1998;22(8):755-61.
117. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51(6):1197-203.
118. Fischer JC, Frick M, Wassmuth R, Platz A, Punzel M, Wernet P. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. British journal of haematology. 2005;130(5):740-6.
119. Liang ZY1, Ren HY. 2008. Factors affecting mobilization of peripheral blood stem/progenitor cells and apheresis efficiency from healthy donors by rhG- CSF. PubMed.gov. [Çevrimiçi] aug 2008. [Alıntı Tarihi: 24 şubat 2018.] https://www.ncbi.nlm.nih.gov/pubmed/. 18718074.
120. Chen j. Burns K. M., Babic A, Carrum G, Kennedy M, Segura F.C, et al. Donor body mass index is an important factor that affects peripheral blood progenitor cell yield in healthy donors after mobilization with granulocyte– colony-stimulating factor. Transfusion and Apheresis Science. 2014;54:203-10. 121. Ozkurt ZN, Yegin ZA, Suyani E, Aki SZ, Acar K, Yagci M, et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. Journal of clinical apheresis. 2010;25(5):280-6.
122. Park IH, Kim Y, Kim JS, Cheong JW, Song JW, Min YH. Transfusion associated iron overload as a predictive factor for poor stem cell mobilization in patients with haematological malignancies. Transfusion medicine. 2008;18(2):97-103.
123. Michael A. Pulsipher, 1 Pintip Chitphakdithai,2 Brent R. Logan,3 Bronwen E. Shaw,4 John R. Wingard,5 Hillard M. Lazarus,6 Edmund K. Waller,7 Matthew Seftel,8 David F. Stroncek,9 Angela M. Lopez,10 Dipnarine Maharaj,11 Peiman Hematti,12 Paul V. O'Donnell,13. 2013. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a